BPTH

Bio-Path Holdings, Inc. [BPTH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BPTH Stock Summary

Top 10 Correlated ETFs

BPTH


Top 10 Correlated Stocks

BPTH


In the News

10:28 28 Mar 2024 BPTH

Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript

Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today's event is being recorded.

07:00 28 Mar 2024 BPTH

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.

05:28 28 Mar 2024 BPTH

Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call.

07:00 28 Mar 2024 BPTH

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.

04:01 28 Mar 2024 BPTH

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.

01:44 28 Mar 2024 BPTH

Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call.

07:00 28 Mar 2024 BPTH

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 15, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023 and to provide a business overview.

09:17 28 Mar 2024 BPTH

Why Is Bio-Path (BPTH) Stock Down 12% Today?

Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.

10:06 28 Mar 2024 BPTH

Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call.

07:00 28 Mar 2024 BPTH

Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023

HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 12, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.

BPTH Financial details

Company Rating
Neutral
Market Cap
2.96M
Income
-16.06M
Revenue
0
Book val./share
0.71
Cash/share
1.7
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.32
Forward P/E
-0.2
PEG
-0.01
P/S
-
P/B
2.11
P/C
2.38
P/FCF
-0.44
Quick Ratio
1.73
Current Ratio
3.54
Debt / Equity
0.26
LT Debt / Equity
0.02
-
-
EPS (TTM)
-6.97
EPS next Y
-20.4
EPS next Q
-4.8
EPS this Y
1670.53%
EPS next Y
192.68%
EPS next 5Y
-854.66%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1606.25%
-
-
-
-
SMA20
-37.66%
SMA50
-57.61%
SMA100
-66.62%
Inst Own
8.03%
Inst Trans
1.4%
ROA
-331%
ROE
-216%
ROC
-4.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
678.8K
Shs Float
660.11K
-
-
-
-
Target Price
-
52W Range
4.01-44.8
52W High
-90.82%
52W Low
+1%
RSI
29.81
Rel Volume
0.59
Avg Volume
19.68K
Volume
11.57K
Perf Week
-16.87%
Perf Month
-55.56%
Perf Quarter
-43.1%
Perf Half Y
-43.97%
-
-
-
-
Beta
0.661
-
-
Volatility
0.24%, 1.54%
Prev Close
0.5%
Price
4.04
Change
8.31%

BPTH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-3.2-2.82-1.55-1.9-33.64
Operating cash flow per share
-3.15-2.85-1.47-2.08-24.13
Free cash flow per share
-3.15-2.85-1.49-2.08-24.13
Cash per share
7.693.583.541.432.2
Book value per share
7.943.923.791.950.92
Tangible book value per share
7.943.923.791.950.92
Share holders equity per share
7.943.923.791.950.92
Interest debt per share
0.160.090.030.030.24
Market cap
424.59M269.29M507.07M219.74M4.43M
Enterprise value
404.58M255.87M483.53M209.57M3.49M
P/E ratio
-49.92-24.81-48.58-15.88-0.28
Price to sales ratio
00000
POCF ratio
-50.78-24.57-51.13-14.55-0.38
PFCF ratio
-50.78-24.57-50.77-14.53-0.38
P/B Ratio
20.1417.8719.9215.510.04
PTB ratio
20.1417.8719.9215.510.04
EV to sales
00000
Enterprise value over EBITDA
-47.81-23.79-47.03-15.27-0.22
EV to operating cash flow
-48.39-23.35-48.76-13.88-0.3
EV to free cash flow
-48.39-23.35-48.42-13.86-0.3
Earnings yield
-0.02-0.04-0.02-0.06-3.63
Free cash flow yield
-0.02-0.04-0.02-0.07-2.61
Debt to equity
0.020.020.010.020.26
Debt to assets
0.020.020.010.010.04
Net debt to EBITDA
2.361.252.290.740.06
Current ratio
17.6813.6527.299.271.6
Interest coverage
000421.240
Income quality
0.971.010.951.090.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
00000
Capex to depreciation
00-0.43-0.120
Stock based compensation to revenue
00000
Graham number
23.9115.7711.59.1326.42
ROIC
-0.39-0.69-0.4-0.95-23.75
Return on tangible assets
-0.38-0.66-0.39-0.87-4.99
Graham Net
7.313.213.371.18-3.61
Working capital
20.75M14.79M25.18M13.93M1.14M
Tangible asset value
21.09M15.07M25.46M14.17M441K
Net current asset value
20.42M14.55M25.03M13.82M263K
Invested capital
0.020.020.010.020.26
Average receivables
387.61K387.61K-261.5-2.06K-1.79K
Average payables
649.5K293K103K386.5K562K
Average inventory
3881.02K8982.06K1.79K
Days sales outstanding
00000
Days payables outstanding
771.26241.72240.311.37K937.11
Days of inventory on hand
1.233.081.197.360
Receivables turnover
00000
Payables turnover
0.471.511.520.270.39
Inventory turnover
296.39118.62307.8449.620
ROE
-0.4-0.72-0.41-0.98-36.46
Capex per share
00-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.54-0.66-0.53-0.32-5.46
Operating cash flow per share
-0.69-0.46-0.41-0.28-2.94
Free cash flow per share
-0.69-0.46-0.41-0.28-2.94
Cash per share
1.430.850.430.231.7
Book value per share
1.951.140.630.250.71
Tangible book value per share
1.951.140.630.250.71
Share holders equity per share
1.951.140.630.250.71
Interest debt per share
0.030.020.020.010.18
Market cap
219.74M221.29M283.38M74.39M5.72M
Enterprise value
209.57M214.75M280.1M72.18M4.78M
P/E ratio
-13.92-10.53-16.73-5.81-0.42
Price to sales ratio
00000
POCF ratio
-43.95-60.58-86.21-26.75-3.15
PFCF ratio
-43.95-60.58-86.21-26.75-3.15
P/B Ratio
15.524.356.1929.4612.98
PTB ratio
15.524.356.1929.4612.98
EV to sales
00000
Enterprise value over EBITDA
-53.19-40.93-66.75-21.86-1.81
EV to operating cash flow
-41.91-58.79-85.21-25.96-2.64
EV to free cash flow
-41.91-58.79-85.21-25.96-2.64
Earnings yield
-0.02-0.02-0.01-0.04-0.59
Free cash flow yield
-0.02-0.02-0.01-0.04-0.32
Debt to equity
0.020.020.030.060.26
Debt to assets
0.010.020.030.030.04
Net debt to EBITDA
2.581.250.780.670.35
Current ratio
9.275.654.393.541.6
Interest coverage
199.3278.53000
Income quality
1.260.690.780.870.54
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
4.884.122.751.349.36
ROIC
-0.27-0.56-0.79-1.14-5
Return on tangible assets
-0.25-0.47-0.65-0.64-1.05
Graham Net
1.180.590.25-0.01-2.79
Working capital
13.93M8.88M4.83M3.45M1.14M
Tangible asset value
14.17M9.11M5.04M2.53M441K
Net current asset value
13.82M8.8M4.78M2.31M263K
Invested capital
0.020.020.030.060.26
Average receivables
-2.97K-2.99K-1.73K-534.50
Average payables
856.5K747K732.5K457.5K367K
Average inventory
2.97K2.99K1.73K534.50
Days sales outstanding
00000
Days payables outstanding
1.31K1.65K1.25K541.961K
Days of inventory on hand
7.024.792.0900
Receivables turnover
00000
Payables turnover
0.070.050.070.170.09
Inventory turnover
12.8218.7843.0300
ROE
-0.28-0.58-0.84-1.27-7.65
Capex per share
00000

BPTH Frequently Asked Questions

What is Bio-Path Holdings, Inc. stock symbol ?

Bio-Path Holdings, Inc. is a US stock , located in Bellaire of Tx and trading under the symbol BPTH

What is Bio-Path Holdings, Inc. stock quote today ?

Bio-Path Holdings, Inc. stock price is $4.04 today.

Is Bio-Path Holdings, Inc. stock public?

Yes, Bio-Path Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap